Amarin’s REDUCE-IT: Winners, Losers, and Suitors Analysis
Recently, Amarin presented REDUCE-IT results at AHA. Although there has been a large volume of news and interpretation on the potential for REDUCE-IT to be practice-changing in preventive cardiology, there has been even more talk about Amarin as the hottest take-out target in the industry, despite the growing short interest post-results. In this original research report, FENIX provides a winners-losers-and-suitors analysis, including the rationale and context for why Amarin could be bought by top suitors before REDUCE-IT’s FDA approval, why popular choice suitors would NOT be interested, how the current regulatory environment works in Amarin’s favor, and what an updated Vascepa label could look like. This report is the advanced read that separates itself from all the other REDUCE-IT trial-related analyses you’ve already seen, covering the Amarin market opportunity from the perspectives of Amgen, Sanofi, Novartis, Merck, Lilly, BI, Janssen, Novo Nordisk, Pfizer, Gilead, Esperion, and The Medicines Company.
An inside advanced look at the section titles
In this original research report by FENIX, the following section titles provide a glimpse of the authors’ deep cardiometabolic expertise and analysis:
- The top Amarin suitors
- Popular choices that don’t quite fit
- Loser: AstraZeneca
- Esperion and The Medicines Company could be affected
- What about…
- Dark horses
- Other relevant thoughts
- The US regulatory environment is highly favorable to reward innovation in cardiometabolic disease
Take action now knowing the full scope of the opportunity and the implications it has on the market.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
This is a 6-page report with hard-hitting, to-the-point insight.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your FENIX Library after signing up.